← Leaderboards
Gary L Simon
George Washington University
$3,463,064
Attributed
$6,589,193
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2021–22$2.5M$1.9M$1.3M$625K$0
'21
'22
Funding mix
By agency
NIH$6,589,193 · 2
By mechanism
UM1$4,689,193 · 1
R01$1,900,000 · 1
Top collaborators
- Sarah Henn2 shared
- Manya Magnus2 shared
Most similar at George Washington University
Same institution · by research overlap
- Alan Edward Greenberg$12,743,754
- Manya Magnus$6,244,258
- Sarah Henn$3,599,297
- Raj M Lakshman$7,988,460
- Marinella Temprosa$73,833,703
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchLow Density Lipoprotein ReceptorComputed Axial TomographyThalidomideProtease InhibitorNuclear Magnetic Resonance SpectroscopyDrug InteractionsGene Induction /RepressionOxidative StressRitonavirTumor Necrosis Factor AlphaAtherosclerosisAntiaids AgentBlood Lipoprotein MetabolismHuman SubjectDrug Adverse EffectAids TherapyTissue /Cell CultureBehavioralAids/Hiv ProblemCohortAreaAids Clinical Trial GroupAffect
Grant awards (7)
The District of Columbia Clinical Trials Unit (DC CTU)$2,406,098
UM1 · FY2022 · AI
The District of Columbia Clinical Trials Unit (DC CTU)$2,283,095
UM1 · FY2021 · AI
PROTEASE INHIBITORS INDUCE AN ATHEROGENIC LIPOPROTEIN$380,000
R01 · FY2004 · HL
PROTEASE INHIBITORS INDUCE AN ATHEROGENIC LIPOPROTEIN$380,000
R01 · FY2003 · HL
PROTEASE INHIBITORS INDUCE AN ATHEROGENIC LIPOPROTEIN$380,000
R01 · FY2002 · HL
PROTEASE INHIBITORS INDUCE AN ATHEROGENIC LIPOPROTEIN$380,000
R01 · FY2001 · HL
PROTEASE INHIBITORS INDUCE AN ATHEROGENIC LIPOPROTEIN$380,000
R01 · FY2000 · HL